HIMS
A regulatory nod, not a victory lap
Hims & Hers Health got a nice little Thursday bounce after an FDA advisory panel voted to place the BPC-157 peptide on the allowed pharmacy compounding list. Translation: the market heard “potentially more room to sell compounded treatments” and immediately reached for the buy button.
The stock was up 5.68% to $33.47 at the time of publication, while the Nasdaq and S&P 500 were both in the red. So yes, Hims was very much doing its own thing here.
Why investors cared
The vote came from the Pharmacy Compounding Advisory Committee during its July 23–24 meetings on bulk lists under the 503A framework. If a peptide makes the 503A Bulk List, state-licensed pharmacies can compound reviewed peptides — which is a pretty big deal for a company like Hims that likes to build revenue by turning healthcare into a more app-friendly checkout experience.
Here’s the catch: this was an advisory panel vote, not the final boss battle. The FDA still has to make its final determination, so the market is reacting to possibility, not certainty.
The setup was already tense
Earlier this month, BofA Securities’ Allen Lutz had flagged that preliminary FDA briefing materials recommended against adding seven peptides, citing safety, quality, and evidence concerns. In other words, the backdrop was already a regulatory soap opera, and today’s vote just gave the plot a twist.
Meanwhile, short interest fell from 65.47 million shares to 61.17 million. That’s still a chunky 31.82% of float, which means there are plenty of skeptics out there — and plenty of fuel if the stock keeps squeezing higher.
Big picture
For Hims, this is the kind of headline that can move the stock fast because it touches the company’s core business model: how freely it can offer and compound certain treatments. The FDA still gets the final say, but for now the market is betting the door just cracked open a little wider.